摘要
目的:观察黄芪注射液治疗扩张型心肌病心力衰竭的临床疗效。方法:选择2013年1月—2014年1月本院住院或门诊收治的扩张型心肌病患者80例,随机分为对照组和治疗组各40例,对照组采用血管紧张素转换酶抑制剂、醛固酮拮抗剂、强心剂、利尿剂、扩血管药物、抗血小板或抗凝剂治疗,根据病情逐渐加用β受体阻滞剂。治疗组在对照组治疗的基础上加用黄芪注射液20 m L加入5%葡萄糖溶液中静脉滴注,日1次,7 d为1个疗程,共治疗4个疗程。结果:治疗组有效率为92.5%,对照组有效率为75.5%,两组有效率比较,差异有统计学意义(P<0.05);治疗组治疗后射血分数为(55.45±5.67),对照组治疗后射血分数为(48.46±5.43),两组比较,差异有统计学意义(P<0.05);治疗组治疗后左心室舒张末期内径为(56.64±2.65)mm,对照组治疗后左心室舒张末期内径为(58.46±2.36)mm,两组比较,差异有统计学意义(P<0.05);治疗组治疗后NT-Pro-BNP为(1 520.56±156.87)ng·L-1,对照组治疗后NT-Pro-BNP为(2 096.78±165.34)ng·L-1,两组比较,差异有统计学意义(P<0.05)。结论:黄芪注射液治疗扩张型心肌病心力衰竭疗效显著。
Objective： To observe the clinical curative effect of Astragalus Membranaceus Injection on heart failure of dilated cardiomyopathy. Methods： Eighty patients with dilated cardiomyopathy who were treated in our hospital between Jan. of 2013 and Jan. of 2014 were chosen as the research objects,and randomly divided into the control group and the treatment group,with 40 cases in each group. The ones in the control group were treated with angiotensin converting enzyme inhibitors,aldosterone antagonists,cardiac,diuretic,expanding blood vessel,antiplatelet and anticoagulant drugs,or gradually added β blockers according to the condition,while the ones in the treatment group were added 20 ml of Astragalus Membranaceus Injection plus Glucose solution with 5% density for venous dripping based on the treatment of the control group,once a day,and 7 days were regarded as one course. Both groups were treated for 4 courses. Results： The effective rate of the treatment group was 92. 5%,while that of the control group was 75. 5%; And the difference between them had statistical significance（ P〈0. 05）. After the treatment,the ejection fraction of the treatment group was（ 55. 45 ± 5. 67）,while that of the control group was（ 48. 46 ± 5. 43）,and the difference between them had significance（ P〈0. 05）. After the treatment,the left ventricular end-diastolic diameter of the treatment group was（ 56. 64 ± 2. 65） mm,while that of the control group was（ 58. 46 ± 2. 36） mm,and the difference between them had significance（ P〈0. 05）. After the treatment,NT-Pro-BNP of the treatment group was（ 1520. 56 ± 156. 87） ng·L- 1,while that of the control group was（ 2096. 78 ± 165. 34） ng·L- 1,and the difference between them had significance（ P〈0. 05）. Conclusion：Astragalus Membranaceus Injection can greatly improve the clinical curative effect of patients with heart failure of dilated cardiomyopathy.
出处
《河南中医》
2016年第8期1349-1351,共3页
Henan Traditional Chinese Medicine
基金
湖北省中医药中西医结合科研课题资助项目(编号:2012-44)
关键词
扩张型心肌病
黄芪注射液
射血分数
左心室舒张末期内径
N末端脑钠肽前体
dilated cardiomyopathy
Astragalus Membranaceus Injection
ejection fraction
left ventricular end-diastolic diameter
N terminal brain natriuretic peptide precursor
